The SURPASS-J-combo trial embraced diabetic adults with HbA 1c 7% to 11% and BMI 23 kg/m 2 , stable weight and uncontrolled with therapy of metformin, thiazolidinedione, sulfonylureas, meglitinide, alpha-glucosidase inhibitor or SGLT2-i (81)
At 1 year the primary outcomes of NACE (cardiac death, target vessel MI [TV MI], target lesion revascularisation [TLR], stent thrombosis and BARC3/5 bleeding) were similar between the two groups, (3.7% vs 4.1%
Lean forward slightly, keeping your back leg straight and your front leg bent
[]
Henry Meds offers multiple oral compounded formats but provides zero educational content about the differences
Initially, the drug was prescribed to control sugar levels in people with Type 2 diabetes